

AMENDMENT

Please amend the claims as follows:

Sub
c 1

1. (Amended) A method for reducing hypersensitivity side effect caused by an amphiphilic carrier, and/or active ingredient comprising administering to a subject a hypersensitivity reducing effective amount of a complement activation inhibitor in conjunction with the active ingredient and the amphiphilic carrier or a pharmaceutical solvent, wherein said amphiphilic carrier is polyethoxylated oil or a derivatized polyethoxylated oil, and wherein the active ingredient is taxol, paclitaxel, Doxil, althesin, cyclosporin, diazepam, didemnin E, echinomycin, propandid, steroids, teniposide, doxorubicin, daunorubicin, amphotericin B, hemoglobin, polynucleotide or multivitamin product.
2. (Amended) The method according to claim 1 wherein said composition further comprises emulsifiers or detergent molecules.
3. (Amended) The method according to claim 2 wherein the pharmaceutical solvent is selected from the group of hydrophilic or hydrophobic solvents.
4. (Amended) The method according to claim 1 wherein the polyethoxylated oil is Cremophor EL.
5. (Amended) The method according to claim 1 wherein said active ingredient is poorly soluble in water-based solvents and necessitates the addition of emulsifiers to become soluble.
6. (Amended) The method according to claim 2 wherein the active ingredient is taxol.